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Lipoprotein(a) (Lp(a)) consists of a low-density
lipoprotein-like particle and a covalently linked highly
glycosylated protein, called apolipoprotein(a) (apo(a)). Lp(a)
derives from the liver but its catabolism is still poorly
understood. Plasma concentrations of this highly atherogenic
lipoprotein are elevated in hemodialysis (HD) patients,
suggesting the kidney to be involved in Lp(a) catabolism. We
therefore compared the in vivo turnover rates of both protein
components from Lp(a) (i.e. apo(a) and apoB) determined by
stable-isotope technology in seven HD patients with those of
nine healthy controls. The fractional catabolic rate (FCR) of
Lp(a)–apo(a) was significantly lower in HD patients compared
with controls (0.16470.114 vs 0.24670.067 days1,
P¼ 0.042). The same was true for the FCR of Lp(a)–apoB
(0.12970.097 vs 0.29970.142 days1, P¼ 0.005). This
resulted in a much longer residence time of 8.9 days for
Lp(a)–apo(a) and 12.9 days for Lp(a)–apoB in HD patients
compared with controls (4.4 and 3.9 days, respectively). The
production rates of apo(a) and apoB from Lp(a) did not differ
significantly between patients and controls and were even
lower for patients when compared with controls with similar
Lp(a) plasma concentrations. This in vivo turnover study is a
further crucial step in understanding the mechanism of Lp(a)
catabolism: the loss of renal function in HD patients causes
elevated Lp(a) plasma levels because of decreased clearance
but not increased production of Lp(a). The prolonged
retention time of Lp(a) in HD patients might importantly con-
tribute to the high risk of atherosclerosis in these patients.
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Cardiovascular morbidity and mortality are markedly
elevated in patients with chronic kidney disease.1 Like other
atherogenic lipoproteins (e.g. intermediate and low-density
lipoproteins (LDLs)), lipoprotein(a) (Lp(a)) has been
suggested to contribute to the high cardiovascular bur-
den.2–7 Lp(a) derives from the liver but sites and mechanisms
of Lp(a) catabolism are still discussed controversially
(reviewed by Utermann8). Animal models have shown that
the kidney may function as a catabolic organ for various
lipoproteins including Lp(a)9 but not for LDL.10 Most studies
in patients with chronic kidney disease treated by peritoneal
dialysis or hemodialysis (HD) revealed significantly elevated
Lp(a) plasma levels which return to pre-disease values after
successful kidney transplantation (reviewed by Kronenberg
et al.11). The elevated Lp(a) levels cannot be explained by
differences in apolipoprotein(a) (apo(a)) isoform frequencies
and are therefore considered non-genetic and caused by the
disease.6,12,13 These findings led to the assumption that the
human kidney might be directly or indirectly involved in
Lp(a)/apo(a) removal and degradation from plasma.
So far, no kinetic studies have been performed to examine
whether elevated Lp(a) levels in HD patients are caused by
increased synthesis and/or decreased catabolism. Decreased
catabolism would be in line with the previously suggested
metabolic function of the human kidney for Lp(a). We
therefore used the technology of stable-isotope-labelled amino
acids to investigate the metabolism of apo(a) and apoB of
Lp(a) in seven HD patients and nine healthy controls.
RESULTS
General parameters
Biometric data, lipids and lipoprotein profiles of HD patients
and healthy controls are summarized in Table 1. In
accordance with former studies (see review by Kronenberg14),
high-density lipoprotein cholesterol levels were lower and
triglyceride levels higher in HD patients than in controls,
whereas total cholesterol, LDL cholesterol, and apoB
concentrations did not differ significantly between the two
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groups. Markers for malnutrition and inflammation such as
total plasma protein, albumin, and C-reactive protein which
are predictors for cardiovascular disease in chronic kidney
patients15 differed slightly between patients and controls but
were still within normal range.
Apo(a) phenotype and Lp(a) concentration
Half of the subjects (1, 2, 3, 4, 7, 8, 10, and 11) expressed one
apo(a) isoform in plasma, whereas the other half (5, 6, 9, 12,
13, 14, 15, and 16) displayed two different apo(a) isoforms
(Table 2). The second, larger isoform, however, was of
markedly lower intensity (o10% of total staining) and could
not be included for sensitivity reasons in the mass-spectro-
metric and kinetic analysis.16 This isoform thus contributes
very little to the total Lp(a) plasma concentration and is
therefore unlikely to significantly influence apo(a) metabo-
lism in these subjects. The mean Lp(a) plasma concentration
was 20% higher in HD patients (50.8728.0 mg/dl) than in
controls (42.3723.0 mg/dl) (Table 2). When we considered
whole blood concentrations, the absolute values of Lp(a)
were markedly lower in patients and controls when calculated
with the formula [Lp(a)plasma * (1hematocrit)] (33.9 vs
23.9 mg/dl; Table 2). The relative difference in Lp(a)
concentrations between patients and controls became more
pronounced, as Lp(a) in HD patients was then distributed in
a larger plasma volume. Similar to an earlier study,17 the
relative difference was twice as high (41%) when calculated
for whole blood levels (Table 2).
Lp(a) turnover rates
Based on the measurement of isotope enrichment, tracer/
tracee ratios were calculated (Figure 1) and converted into
final kinetic parameters.
The fractional catabolic rate (FCR) of Lp(a)–apo(a) was
significantly lower in HD patients than in controls (0.164 vs
0.246 days1, P¼ 0.042). The same was true for the FCR of
Lp(a)–apoB (0.129 vs 0.299 days1, P¼ 0.005) (Table 2 and
Figure 2). This resulted in a 2–3 times longer residence time
(RT) for Lp(a)–apo(a) (8.85 vs 4.39 days, P¼ 0.042) and
Lp(a)–apoB (12.86 vs 3.91 days, P¼ 0.008) in HD patients
compared with controls. Interestingly, the RT of the two
proteins was very similar in controls (4.39 vs 3.91 days,
P¼ 0.260) but significantly different in patients (8.85 vs
12.86 days, P¼ 0.028). The production rate (PR) of apo(a)
and apoB from Lp(a), which equals the product of FCR,
Lp(a) blood concentration, and blood volume, did not differ
significantly between controls and HD patients at a first
glance (1.161 vs 1.109 nmol/kg for Lp(a)–apo(a) and 1.283 vs
0.832 nmol/kg for Lp(a)–apoB). However, when we per-
formed a paired comparison of the FCR of Lp(a)–apo(a) and
Lp(a)–apoB from patients and controls with similar molar
Lp(a) blood concentrations, we observed, with one excep-
tion, clearly lower FCR levels in patients (Table 3). This
consequently resulted in a decreased PR of Lp(a)–apo(a) and
Lp(a)–apoB in HD patients compared with controls. As
expected, the apo(a) PR significantly correlated with plasma
Lp(a) concentrations in controls (r¼ 0.717, P¼ 0.030),
Table 1 | Biometric data, proteins, lipids, and lipoproteins in plasma from controls and hemodialysis patients
Subjects
Age
(years)
BMI
(kg/m2)
Prot.
(g/dl)
Alb
(g/dl)
CRP
(mg/l)
Chol.
(mg/dl)
HDL-C
(mg/dl)
TG
(mg/dl)
LDL-C
(mg/dl)
ApoB
(mg/dl)
Duration HD
(months)
Creatinine
(mg/dl)
Urea
(mg/dl)
Controls
1 28 21.0 6.4 3.9 2.1 99 31 79 52 43
2 21 22.0 7.0 4.4 0.1 187 56 90 113 94
3 50 27.6 5.8 3.6 5.8 204 36 216 125 125
4 27 22.3 6.5 4.2 1.9 141 34 86 90 66
5 32 24.2 7.4 4.5 4.0 299 41 91 240 194
6 23 22.5 6.5 4.1 2.0 150 37 100 93 150
7 42 24.6 7.0 4.0 0.1 154 52 50 92 97
8 36 30.6 7.0 4.8 1.0 196 45 124 126 116
9 43 25.4 6.3 4.0 2.0 170 42 57 117 98
Patients
10 33 20.6 6.7 4.2 2.0 126 29 127 72 100 108 13.5 170
11 61 24.5 7.1 3.7 2.0 253 35 250 168 163 34 12.4 160
12 35 23.5 6.6 3.9 5.0 174 25 160 117 97 5 9.3 146
13 67 18.4 6.4 3.6 3.3 262 38 166 191 154 41 9.7 94
14 31 26.5 6.7 3.9 4.7 184 27 140 129 163 75 13.4 193
15 60 21.0 6.6 3.7 8.0 194 45 63 136 102 27 9.0 63
16 61 22.3 6.5 3.6 12.0 168 31 111 115 84 44 13.0 175
Controls
n=9
34710 24.573.1 6.770.5 4.270.4 2.171.8 178756 4278 99749 116752 109745
HD patients
n=7
50716 22.472.7 6.770.2 3.870.2 5.373.6 194748 3377 145758 133739 123735 48734 11.572.0 143747
P-value 0.055 0.21 0.75 0.03 0.04 0.61 0.055 0.055 0.21 0.41
Alb, albumin; BMI, body mass index; Chol., cholesterol; CRP, C-reactive protein; HD, hemodialysis; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-
cholesterol; Prot., protein; TG, triglycerides.
Values are means7s.d.
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whereas it did not reach statistical significance in HD patients
(r¼ 0.607, P¼ 0.148).
Table 4 shows the rate constants for each individual
pathway depicted in the multicompartmental kinetic Lp(a)
model (Figure 3). Comparing the rate constants for the
hepatic and LDL-derived apoB moiety of Lp(a) (d(5,2) and
k(5,4)) revealed that Lp(a) is almost exclusively (92% in
controls, 99% in HD patients) synthesized directly from the
liver. The remaining 8% and 1%, respectively, are derived
from plasma LDL. The fractional standard deviation values
Table 2 | Lipoprotein(a) and kinetic data in controls and hemodialysis patients
Subjects
Lp(a) plasma
(mg/dl)
Apo(a)
isoform Hematocrit
Lp(a) blood
(mg/dl)
Lp(a) blood
(nM)
Apo(a)-FCR
(days1)
ApoB-FCR
(days1)
Apo(a)-RT
(days)
ApoB-RT
(days)
Apo(a)-PR
(nmol/kg d)
ApoB-PR
(nmol/kg d)
Controls
1 37.2 13 0.42 21.7 66.21 0.133 0.232 7.52 4.31 0.616 1.075
2 60.7 19 0.45 33.4 99.07 0.278 0.183 3.60 5.47 1.928 1.269
3 49.0 20 0.48 25.5 75.27 0.191 0.205 5.24 4.88 1.006 1.080
4 92.1 20 0.37 58.1 171.68 0.214 0.203 4.67 4.93 2.572 2.440
5 35.2 22/34 0.45 19.4 56.61 0.316 0.367 3.16 2.72 1.252 1.454
6 16.6 24/29 0.45 9.1 26.46 0.229 0.202 4.37 4.95 0.424 0.374
7 19.5 26 0.49 10.0 28.50 0.314 0.568 3.18 1.76 0.626 1.133
8 34.0 30 0.45 18.7 52.74 0.331 0.489 3.02 2.04 1.222 1.805
9 36.2 32/35 0.46 19.6 54.60 0.210 0.240 4.76 4.17 0.803 0.917
Patients
10 42.9 20 0.33 28.7 84.91 0.095 0.073 10.53 13.70 0.565 0.434
11 48.0 21 0.33 32.2 94.59 0.403 0.316 2.48 3.16 2.668 2.092
12 48.1 22/37 0.39 29.3 85.79 0.045 0.028 22.22 35.71 0.270 0.168
13 111.0 25/34 0.30 77.4 223.28 0.133 0.079 7.52 12.66 2.079 1.235
14 31.1 26/33 0.34 20.4 58.71 0.142 0.080 7.04 12.50 0.584 0.329
15 48.0 28/34 0.34 31.8 90.53 0.155 0.146 6.45 6.85 0.982 0.925
16 26.5 30/33 0.33 17.7 49.92 0.176 0.183 5.68 5.46 0.615 0.639
Controls n=9 42.3723.0 23.675.9 0.4570.04 23.9714.8 70.1744.1 0.24670.067 0.29970.142 4.3971.42 3.9171.38 1.16170.696 1.28370.582
HD patients
n=7
50.8728.0 24.673.7 0.3470.03 33.9720.0 98.2757.6 0.16470.114 0.12970.097 8.8576.36 12.86710.86 1.10970.904 0.83270.664
P-value – 0.61 0.46 o0.001 0.21 0.21 0.042 0.005 0.042 0.008 0.47 0.14
Controls/HD+
P-value – Controls 0.139 0.314 0.260
apo(a)/apoB++ Patients 0.028 0.028 0.028
Apo(a), apolipoprotein(a); FCR, fractional catabolic rate; HD, hemodialysis; Lp(a), lipoprotein(a); RT, retention time; PR production rate.
Values are means7s.d. +Mann–Whitney U-test for comparison of controls vs patients, ++paired Wilcoxon test for comparison of FCR, RT, and PR of apo(a) and apoB moieties
of Lp(a) from a given subject, stratified for patients and controls.
1.000
0.100
0.010
Lp(a)-apoB
Lp(a)-apo(a)
0.001
0 2 4
4
6 8 10
0 2
Time (h)
6 8 10
Tr
a
ce
r/t
ra
ce
e
 r
a
tio
s 
(%
)
1.000
0.100
0.010
0.001
Figure 1 | Tracer/tracee ratio curves for Lp(a)–apoB (upper panel)
and Lp(a) –apo(a) (lower panel) in seven HD patients (squares)
and nine control subjects (circles). Plasma concentrations of
Lp(a) did not change at any time point during the study, indicating
steady-state conditions. Data are given as mean7s.e. and were fitted
by the multicompartmental model using SAAMII.
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Figure 2 | Significantly decreased FCR of Lp(a)–apo(a) and
Lp(a)–apoB in seven HD patients compared with nine healthy
controls.
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for k(0,4), k(0,5), and k(0,7) were 6.774.7, 16.0717.7, and
6.773.3%, respectively. The fractional standard deviation for
k(5,4) could not be adequately calculated because of
extremely low rate constants for this pathway.
DISCUSSION
In this study, we investigated the turnover of Lp(a) in seven
HD patients and nine healthy controls. This endogenously
labelled stable-isotope amino-acid technology allows simul-
taneous analysis of the two protein components of Lp(a),
namely apo(a) and apoB.18
The observed significantly decreased FCR of Lp(a)–apo(a)
(33%) and Lp(a)–apoB (57%) together with a 41%
higher whole blood Lp(a) concentration in HD patients
compared with controls argues for a catabolic block caused
by kidney dysfunction. Our turnover study is one further
important step in understanding Lp(a) catabolism and in line
Table 3 | Comparison of apo(a)-FCR and apoB-FCR between
all possible pairs of controls and patients with a difference in
Lp(a) blood concentration of less than715%
Lp(a) blood (nM) Apo(a)-FCR (days1) ApoB-FCR (days1)
Control Patient Control Patient Change Control Patient Change
52.74 49.92 0.331 0.176 + 0.489 0.183 +
58.71 0.331 0.142 + 0.489 0.080 +
54.60 49.92 0.210 0.176 + 0.240 0.183 +
58.71 0.210 0.142 + 0.240 0.080 +
56.61 49.92 0.316 0.176 + 0.367 0.183 +
58.71 0.316 0.142 + 0.367 0.080 +
66.21 58.71 0.133 0.142 ) 0.232 0.080 +
75.27 84.91 0.191 0.095 + 0.205 0.073 +
85.79 0.191 0.045 + 0.205 0.028 +
99.07 84.91 0.278 0.095 + 0.183 0.073 +
85.79 0.278 0.045 + 0.183 0.028 +
90.53 0.278 0.155 + 0.183 0.146 +
94.59 0.278 0.403 * 0.183 0.316 *
Apo(a), apolipoprotein(a); FCR, fractional catabolic rate.
The arrow indicates the deviation of the FCR in a given patient when compared with
a respective matched control.
Table 4 | Rate constants (pools/h) for individual pathways shown in Figure 3 in controls and hemodialysis patients
Subjects d(3,2) d(4,2) d(5,2) k(4,3) k(5,4) k(0,3) k(0,4) k(0,5) k(0,7)
Controls
1 0.0440 0.8631 0.0929 0.109 0.00027 0.0000 0.0140 0.0097 0.0056
2 0.6809 0.2919 0.0272 0.093 0.00000 1.3285 0.0124 0.0076 0.0116
3 0.4076 0.5778 0.0146 0.103 0.00015 0.2085 0.0249 0.0085 0.0079
4 0.7528 0.1855 0.0617 0.044 0.00025 0.3643 0.0128 0.0084 0.0089
5 0.6450 0.3177 0.0373 0.962 0.00000 0.0000 0.0127 0.0153 0.0132
6 0.9962 0.0000 0.0039 1.749 0.00002 0.0000 0.0380 0.0084 0.0095
7 0.0496 0.9213 0.0291 0.148 0.00009 0.1311 0.0223 0.0237 0.0131
8 0.3059 0.6159 0.0782 0.330 0.00000 0.0000 0.0112 0.0204 0.0138
9 1.0000 0.0000 0.0000 0.054 0.00000 0.5325 0.0093 0.0100 0.0088
Patients
10 0.9642 0.0000 0.0358 0.751 0.00000 0.0000 0.0067 0.0030 0.0040
11 0.9235 0.0546 0.0219 0.007 0.00003 0.4154 0.0018 0.0132 0.0168
12 0.9221 0.0702 0.0077 0.031 0.00000 0.1375 0.0028 0.0012 0.0019
13 0.0818 0.8728 0.0454 0.126 0.00000 0.2322 0.0088 0.0033 0.0056
14 0.9971 0.0000 0.0029 0.086 0.00000 0.2259 0.0087 0.0033 0.0059
15 0.3985 0.5546 0.0469 1.353 0.00002 0.5209 0.0081 0.0061 0.0065
16 0.9858 0.0000 0.0142 0.094 0.00000 0.1984 0.0072 0.0076 0.0073
Controls n=9 0.54270.363 0.41970.344 0.03870.033 0.39970.583 0.0000970.00011 0.2849870.43456 0.0175170.00928 0.0124570.00593 0.0102670.00280
Patients n=7 0.75370.363 0.22270.350 0.02570.018 0.35070.512 0.0000170.00001 0.2471870.17292 0.0063170.00286 0.0053870.00404 0.0068470.00475
P-value+ 0.351 0.252 0.536 0.536 0.210 0.536 o0.001 0.005 0.042
k(i,j) describes the transfer of leucine from compartment j to compartment i; d(i,2) describes the distribution of material leaving the delay compartment 2 and entering
compartments 3, 4, 5; d(3,2)+d(4,2)+d(5,2)=1.
Values are means7s.d.; +Mann–Whitney U-test.
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Figure 3 | Multicompartmental model for apoB-100 and apo(a)
metabolism. The model consists of a plasma leucine pool
(compartment 1), used as a forcing function, and delay compartments
that account for assembly and subsequent secretion of apoB-100
(compartment 2) and apo(a) (compartment 6), respectively. ApoB in
VLDL, LDL, Lp(a), and apo(a) in Lp(a) consist all of single compartments.
The input of apoB in Lp(a) is twofold: one via de novo synthesis from
the liver and one from LDL-apoB. d(i,j) denotes the distribution of
transfer from the delay compartment j to compartment i and k(i,j)
represents the rate constant from compartment j to compartment i.
In this model, tracer/tracee data for VLDL, LDL, Lp(a)–apoB, and
Lp(a)–apo(a) as well as leucine masses (nmol/l) in these compartments
were fitted simultaneously. The FCR of Lp(a)–apo(a) and Lp(a)–apoB
was equal to k(0,7) and k(0,5), respectively.
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with previous studies suggesting the kidney to be involved in
the metabolism of Lp(a). Kronenberg et al.19 measured Lp(a)
levels in the ascending aorta and renal vein in 100 patients
with normal kidney function. Lp(a) levels differed signifi-
cantly between the two blood vessels with lower values in the
venous samples.19 The authors suggested a removal of Lp(a)
from the renal circulation and assigned the kidney a
potentially active role in the catabolism of Lp(a). Oida
et al.20 showed that urinary Lp(a) excretion correlates
positively with kidney function, although the mechanisms
involved were unclear. Previous findings of proteolytic apo(a)
fragments up to a size of 215 kDa in human urine suggest an
active transport mechanism rather than simple glomerular
filtration.21,22 An active and direct role of the kidney in
catabolizing Lp(a) was supported by intra-glomerular
localization of apo(a)/apoB and localization of apo(a) in
tubular cells in a heterologous rat model after injection of
human Lp(a).9
In this study, there was a mean age difference of 16 years
between patients and controls which could have influenced the
kinetic data of this study as shown earlier for LDL–apoB.23
However, a subanalysis of an age-matched sample of six
controls (subjects 1, 2, 4, 5, 6, and 8, mean age 28 years) and
three patients (subjects 10, 12, and 14, mean age 33 years)
revealed similar results with a significantly decreased FCR
of Lp(a)–apo(a) (0.09470.049 vs 0.250þ 0.074 days1, P¼
0.048) and Lp(a)–apoB (0.06070.028 vs 0.27970.123 days1,
P¼ 0.024) in patients compared with controls. Therefore, the
observed kinetic results cannot be explained by age differences
between patients and controls.
The pair-wise comparison of kinetic parameters from
patients and controls with similar Lp(a) blood levels
provided an interesting detail (Table 3): HD patients had
lower FCR and consequently lower PR values compared with
controls. This finding could suggest an inhibitory feedback
mechanism on Lp(a) synthesis in response to impaired
clearance and subsequently increased plasma concentrations
in HD patients.
The FCR and hence RT values of Lp(a)–apo(a) and
Lp(a)–apoB were very similar in controls suggesting the
clearance of Lp(a) as an integral particle from the circulation.
These findings are consistent with previous studies using
stable isotopes24,25 but inconsistent with a recent kinetic
Lp(a) study in non-fasting probands.26 In this latter study,
Lp(a) was purified from plasma by lectin-mediated affinity
chromatography which could have resulted in co-purification
of other, minor apo(a)-containing plasma fractions that
might have influenced the kinetic analysis. In our study, the
mean RT of Lp(a)–apoB was significantly prolonged
compared with Lp(a)–apo(a) in HD patients (12.86 vs 8.85
days, P¼ 0.028). Whether these differences indicate a
preferential clearing of Lp(a)–apo(a) compared with the
apoB moiety of Lp(a) in HD patients or simply reflect
technically caused variation in a relatively small sample
remains presently unclear. Metabolic studies in larger patient
groups are therefore needed to clarify whether these
differences do reflect different metabolic fates for both
Lp(a) protein components.
PR values of apo(a) correlated significantly with plasma
Lp(a) levels in controls which has been shown in previous
kinetic studies27 indicating regulation of Lp(a) levels
predominantly by synthesis and not by degradation. Such a
significant correlation was not observed in the HD group
underlining the non-genetic and disease-induced origin of
elevated Lp(a) levels in these patients.12,13
Calculation of individual rate constants for each pathway
(Table 4, Figure 3) revealed a further important detail: Lp(a)
was almost exclusively (92% in controls, 99% in HD patients)
derived from the liver and only to a very small extent from
the circulating LDL plasma compartment indicating a very
similar Lp(a) assembly pathway in healthy controls and HD
patients. This finding is compatible with the formation of an
Lp(a) particle within the hepatocyte or on its surface in a
compartment protected from plasma LDL as suggested by Su
et al.,25 but in contrast to several in vitro studies assuming
extracellular or plasma membrane-associated Lp(a) assembly
from circulating LDL (reviewed by White and Lanford28).
Our turnover study and one describing patients with
nephrotic syndrome29 point, however, to fundamental
differences in the metabolism of Lp(a) and other proteins
between these two patient groups. Patients with nephrotic
syndrome showed no differences in the FCR of Lp(a)
compared with controls but an increased synthesis rate of
Lp(a). It is well known that nephrotic patients show a
generally increased synthesis of lipoproteins.29,30 Decreased
clearance of Lp(a) in these patients might not necessarily be
expected, as renal function is still relatively preserved.
Metabolic differences between nephrotic and dialysis patients
are not only evident for Lp(a) but also for albumin. Whereas
FCR of albumin in HD patients is similar or even reduced
compared with controls, FCR in patients with nephrotic
syndrome is increased.31,32
The above-mentioned observation of markedly decreased
FCR of apo(a) and apoB in Lp(a) causes a prolonged RT of
Lp(a) in plasma of HD patients. This is reminiscent of a
recently described disturbed plasma turnover of IDL and LDL
in HD patients: the observed decreased FCR and fractional
synthesis rate of apoB of both IDL and LDL led to the
paradox of a prolonged RT of LDL despite normal circulating
plasma levels.33 Owing to the long retention period, ‘aged’
lipoprotein complexes are thus more susceptible for altera-
tions such as oxidation damage, which was shown to be
associated with accelerated atherogenesis in HD patients.34
A previous kinetic study investigated the turnover of the two
LDL subclasses, ‘buoyant’ LDL1 and the smaller cholesterol-
poor ‘dense’ LDL2, in subjects with familial defective apoB-
100. The authors found a more than four-fold longer RT for
small dense LDL2 in those patients as compared to
normolipidemic controls.35 It was therefore suggested that
oxidative damage of an ‘aged’ LDL2, which is present in large
concentrations in both blood and the subendothelial space,
may be an important mechanism for the development of
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premature atherosclerosis in patients with familial defective
apoB-100. Considering that the LDL particle from Lp(a) is
compositionally similar to LDL2,
24 it is tempting to speculate
that the increased RT of circulating Lp(a) might pose an
additional risk factor for the increased incidence of
cardiovascular disease in HD patients.
Limitations of the study
Similar to other kinetic studies,29,31,32 this study is limited
by its small number of subjects. However, owing to the
labor- and cost-intensive nature of these experiments, a
high-throughput investigation is far from being feasible.
We had to exclude subjects with plasma Lp(a) concentra-
tions o10 mg/dl for technical reasons, as this would not
allow to purify Lp(a) in sufficient quantities. This resulted
together with the relatively small sample size in a non-
significant 41% difference in Lp(a) blood levels between
patients and controls. On the other hand, this allowed us in a
subanalysis to match patients and controls with similar Lp(a)
concentrations, which might be the most appropriate
procedure to investigate differences in the metabolism, which
are not simply caused by Lp(a) plasma concentration
differences between patients and controls.
In summary, this in vivo turnover study supports the role
of the kidney in the clearance of Lp(a)/apo(a) without
providing direct evidence for renal Lp(a) uptake. The lack of
renal function in HD patients might explain the elevated
circulatory levels of Lp(a) because of decreased clearance and
not increased production of Lp(a). The prolonged RT of
Lp(a) in HD patients compared with controls might pose a
further strong contribution to the high risk of atherosclerosis
in these patients.
MATERIALS AND METHODS
Study subjects
Seven HD patients and nine healthy controls – all male Caucasians
from Tyrol, Austria – were enrolled in the study. None of the
subjects showed any evidence of illness affecting lipid metabolism at
the time of the study. The HD patients took vitamins, erythropoie-
tin, and bicarbonate but no medication known to affect Lp(a)
metabolism. For methodological reasons, we enrolled only subjects
who had Lp(a) plasma concentrations 410 mg/dl and who
expressed either a single apo(a) band or a second larger apo(a)
band with minor intensity (o10% of total intensity). For 3 days
preceding the study, all subjects received a standardized isocaloric
diet composed of 30 kcal/kgBW, 50% carbohydrates, 30% fat, and
20% protein with a maximum of 300 mg cholesterol per day. The
primary reasons for the development of end-stage renal disease in
our patients were pyelonephritis (subjects 10 and 11), small kidney
(subjects 13 and 16), Goodpasture syndrome (subject 14), renal
arterial stenosis (subject 15), and IgA nephritis (subject 12). They
had been dialysed for 4 h three times weekly for 48731 months on
average and showed no residual urinary output.
Study protocol
The previously described study protocol36 was approved by the
Internal Review Boards of the Universities of Marburg and
Innsbruck. Written informed consent was obtained from all
participants. The study started after a 10-h overnight fasting period
(in all HD patients 1 day after dialysis), whereby all study subjects
maintained their fasting state during the first 12 h of the study. The
day after dialysis was chosen to ensure that no blood volume shifts
occur within the study period, which would not allow steady-state
conditions. After a starting bolus of 1.34 mg trideuterated L-leucine/
kgBW (95% pure, Cambridge Isotopes Laboratories Inc., Andover,
MA, USA) to an antecubital vein, a continuous infusion of 1.34 mg
d3-leucine/kgBW/h followed. Before bolus injection and during
constant infusion for 10 h, 9 ml ethylenediaminetetraacetic acid
blood samples were taken from the opposite antecubital vein after
10, 20, 30, 40, 60, 90, 120 min followed by hourly blood withdrawal
until 10 h after start of infusion.
Lp(a) preparation
After ethylenediaminetetraacetic acid plasma was obtained by low-
speed centrifugation, Lp(a) was isolated as follows: after removal of
very low-density lipoprotein (VLDL) (do1.006 mg/ml) and LDL
(1.019odo1.063 mg/ml) by sequential ultracentrifugation, Lp(a)
was isolated from the remaining plasma fraction by immunomag-
netic separation with antibody-bound magnetic beads (Magna-
BindTM carboxylated derivatized beads, Pierce, Rockford, IL, USA),
according to the manufacturer’s recommendations. Monoclonal
anti-apo(a) antibody 1A2, which recognizes the repetitive kringle IV
type 2 of apo(a),37 was mixed with magnetic beads at a weight ratio
of 1:50 (wt/wt) and incubated for 45 min at room temperature on a
rotator in a final volume of 1 ml phosphate-buffered saline. After
removal of all unbound antibody by means of an external magnetic
field, VLDL/LDL-depleted plasma (0.1–0.6 ml, depending on Lp(a)
plasma concentration) was incubated overnight with 1.7 mg anti-
body-bound beads at 41C. Afterwards the beads/antibody/Lp(a)
complex was washed in phosphate-buffered saline. With this
purification protocol, on average 60% of Lp(a) could be recovered
which was comparable to previous work38 and which was
substantially higher than achieved with conventional sequential
ultracentrifugation (approximately 15%, according to previous
observations in our laboratory). To assess for purity, Lp(a) was
subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis under non-reducing conditions followed by silver
staining. Lp(a) was found to be pure, not degraded/fragmented and,
in particular, not contaminated with LDL. Likewise, purified VLDL
and LDL did not contain Lp(a)/apo(a) (Figure 4). To separate the
two protein components of Lp(a), Lp(a)–apo(a), and Lp(a)–apoB,
a sample buffer (ratio 1:1.5:15 b-mercaptoethanol, 0.5% bromphe-
nol blue (wt/vol) in 5% glycerol (vol/vol), 10% SDS (wt/vol)) was
added and the solution boiled in a water bath for 10 min. To extract
and prepare both proteins for preparative SDS-polyacrylamide gel
electrophoresis (8%) under reduced conditions, an external
magnetic field was again used.
Mass-spectrometric and kinetic analysis
Both protein bands, corresponding to Lp(a)–apo(a) and Lp(a)–apoB,
were excised from the gel after SDS-polyacrylamide gel electro-
phoresis, dried overnight at 601C, hydrolyzed in 6 M HCl at 1101C
for 24 h under nitrogen and afterwards lyophilized. In case of
subjects with two visible apo(a) isoforms, only the major apo(a)
band was excised and analyzed. Free amino acids were analyzed by
gas chromatography as described by Schweer et al.16 Briefly, free
amino acids were prepared from plasma by cation exchange
chromatography, derivatized, and analyzed by gas chromatogra-
phy/triple-stage quadrupole mass spectrometry. Isotopic enrichment
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was converted to tracer/tracee ratios as described previously.39
A multicompartmental model (SAAMII, Washington University,
Seattle, WA, USA) was developed40 to define the kinetics of
Lp(a)– apo(a) and Lp(a)–apoB, as shown in Figure 3. Based on
previous kinetic studies, plasma Lp(a) was assumed to be assembled
both from circulating and de novo secreted LDL.24
Plasma concentrations of Lp(a), apoB, triglycerides, total and
high-density lipoprotein cholesterol did not change at any time
point during the study (data not shown), indicating steady-state
conditions. Therefore, the fractional synthesis rate was assumed to
be equal to the FCR. RT equals 1/FCR.
As hematocrit levels are remarkably lower in HD patients than in
controls, lipoproteins including Lp(a) distribute in a larger plasma
volume in these patients than in controls.17 Therefore, lipoprotein
levels measured in HD patients are generally too low when the lower
hematocrit is not considered. To account for the significantly
decreased hematocrit in HD patient, we calculated concentrations of
Lp(a) in whole blood from both groups with the formula
[Lp(a)plasma * (1hematocrit)]17 to evaluate PR. The resulting PR
equals the product of FCR * Lp(a) blood concentration * blood
volume (assumed to be 7% of body weight) divided by body weight
as described previously41 with modifications for blood concentra-
tion and blood volume42 instead of plasma concentration and
plasma volume.
Laboratory procedures
Triglycerides, total and high-density lipoprotein cholesterol were
determined with kits from Roche Diagnostics GmbH (Mannheim,
Germany). LDL-cholesterol was calculated with the Friedewald
formula. Urea, creatinine, total protein, albumin, and C-reactive
protein were determined using standard assays on a COBAS
INTEGRAs analyzer (Roche Diagnostics, Mannheim, Germany).
Plasma concentrations of Lp(a) and apoB were measured by double-
antibody enzyme-linked immunosorbent assay as described pre-
viously.43 In short, an affinity-purified polyclonal apo(a) coating
antibody and the horseradish peroxidase-conjugated monoclonal
detection antibody 1A237 was used for Lp(a) determination. To
measure apoB levels, an affinity-purified rabbit polyclonal antibody
against apoB was used for coating and the same antibody, labelled
with horseradish peroxidase, was used for detection. Apo(a)
phenotyping was performed by SDS agarose gel electrophoresis
under reducing conditions.3 The molecular weight of Lp(a) to
calculate PR was equal to the molecular weight of the LDL moiety of
Lp(a)þmass of apo(a) isoform, which was derived from the amino-
acid composition of the protein multiplied by the carbohydrate
moiety (30%) of apo(a).44–46 The PR was indicated in nmol/kg day
in order to distinguish between PRs of apo B and apo(a) (of
different size isoforms) from Lp(a).
Statistical analysis
Data are presented as mean7s.d., except when noted. For statistical
analysis, we used the non-parametric Mann–Whitney U-test and the
paired Wilcoxon test. Correlation was analyzed by Spearman-Rho
test. A Po0.05 was considered significant.
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